Modified FOLFOX-6 Plus Bevacizumab May Be Effective for Liver-Only Metastases of Colorectal Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, modified FOLFOX-6 (leucovorin, fluorouracil, oxaliplatin) plus bevacizumab caused a high rate of hepatectomy and allowed for a high number of initially unresectable cases of liver-only metastases of colon cancer to be resectable.
For the phase 2 clinical study, researchers enrolled 46 patientss with colorectal cancer with liver-only metastases. All patients received mFOLFOX-6 plus bevacizumab for six cycles, and following chemotherapy, a hepatectomy was performed if possible.
Results showed that 18 of 19 patients considered unresectable prior to therapy completed treatment and underwent hepatectomy and 6 of 26 patients considered initially unresectable underwent hepatectomy. In all, approximately 45% of the 45 patients included in the efficacy analysis were R0-resected.
The most common severe adverse events associated with chemotherapy were fatigue, leukopenia, and neutropenia, and the only adverse events associated with bevacizumab were hypertension and venous thromboembolism.
Of the 25 patients who underwent hepatectomy, two experienced grade 3 wound infections, one experienced blioma, one had delayed wound healing, and one had an intraperitoneal abscess intraoperatively or postoperatively.
Modified FOLFOX-6 (leucovorin, fluorouracil, oxaliplatin) plus bevacizumab caused a high rate of hepatectomy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear